AARTIDRUGS437.00

Aarti Drugs Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersALIVUSAARTIPHARMADVENZYMESAGARWALEYEAKUMSAPLLTDCORONAHCGMcap ₹3,988 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,528.62,387.02,565.32,677.6
Other Income4.016.42.42.9
Total Income2,532.62,403.42,567.72,680.5
Expenses
+ Cost of Materials Consumed1,572.01,438.31,504.01,616.1
+ Purchases of Stock-in-Trade80.284.3115.1107.9
+ Changes in Inventories25.519.5-0.4-51.0
+ Employee Benefit Expense102.3112.1129.3135.0
+ Finance Costs33.535.933.734.4
+ Depreciation & Amortisation51.555.867.070.7
+ Other Expenses432.1445.8508.1536.3
Total Expenses2,297.12,191.62,356.82,449.4
EBITDA316.5287.1309.2333.3
EBIT265.0231.3242.2262.6
Profit
PBT before Exceptional Items235.5211.8210.9231.1
+ Exceptional Items0.00.00.0-2.1
Pretax Income235.5211.8210.9229.0
+ Current Tax59.641.213.335.9
+ Deferred Tax4.42.52.72.1
Tax Expense63.943.716.037.9
Net Income171.6168.1194.9191.1
+ Net Income — Continuing Ops171.6168.1194.9191.1
+ Other Comprehensive Income0.11.63.23.1
Total Comprehensive Income171.7169.7198.1194.2
Net Income to Common171.4168.2194.9191.2
Minority Interest0.2-0.10.0-0.1
Per Share
Basic EPS18.5618.3521.3620.93
Diluted EPS18.5618.3521.3620.93
Other Comprehensive Income — detail
+ Other Comprehensive Income1.63.23.1
+ Items NOT to be Reclassified to P&L0.11.63.23.1
Comprehensive Income — Owners of Parent171.5169.7198.1194.3
Comprehensive Income — Non-controlling Interests0.1-0.00.0-0.1
Per Share — as-filed variants
Basic EPS — Continuing Operations18.5618.3521.3620.93
Diluted EPS — Continuing Operations18.5618.3521.3620.93
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit850.9844.9946.61,004.6
Gross Margin %33.6535.4036.9037.52
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)235.5211.8210.9231.1
− Exceptional Items (reconciliation)0.00.00.0-2.1
Net Income Adj (tax-effected)171.6168.1194.9192.8
EPS Adj18.5618.3521.3621.12
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital91.991.391.391.3
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.